Eli Lilly and Company $LLY Stake Decreased by Formuepleje A S

Key Points

• Formuepleje A S reduced its Eli Lilly stake by 21.6% in the third quarter, selling 1,005 shares and retaining 3,638 shares valued at approximately $4.21 million. Institutional investors collectively own 82.53% of the company.
• Eli Lilly reported strong operating momentum, with quarterly revenue rising 47.7% year over year to $22.97 billion and earnings of $8.38 per share, well above the $6.40 consensus estimate. The company reaffirmed fiscal 2026 EPS guidance of $35.50 to $36.50.
• Analysts remain broadly bullish, but valuation is elevated. The stock has a “Moderate Buy” consensus rating and a $1,313.43 average price target, while shares trade near their 52-week high at a P/E ratio of about 42.

Formuepleje A S trimmed its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 21.6% in the 3rd quarter, according to its most recent filing with the SEC. The institutional investor owned 3,638 shares of the company's stock after selling 1,005 shares during the quarter. Formuepleje A S's holdings in Eli Lilly and Company were worth $4,209,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in the stock. BlackRock Inc. increased its position in Eli Lilly and Company by 1.6% during the second quarter. BlackRock Inc. now owns 67,540,400 shares of the company's stock valued at $81,009,981,000 after acquiring an additional 1,046,558 shares during the last quarter. State Street Corp raised its holdings in Eli Lilly and Company by 1.7% in the 2nd quarter. State Street Corp now owns 36,215,754 shares of the company's stock worth $43,438,262,000 after purchasing an additional 605,752 shares during the period. Bank of America Corp DE bought a new stake in Eli Lilly and Company during the second quarter valued at about $13,522,666,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in Eli Lilly and Company by 1.9% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 7,209,385 shares of the company's stock worth $8,647,153,000 after buying an additional 137,364 shares in the last quarter. Finally, Jennison Associates LLC lifted its position in shares of Eli Lilly and Company by 7.9% during the 2nd quarter. Jennison Associates LLC now owns 5,461,416 shares of the company's stock valued at $6,550,587,000 after buying an additional 400,538 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company's stock.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Omvoh data strengthen Lilly’s immunology franchise. In the LUCENT-2 trial, 27.7% of ulcerative-colitis patients achieved comprehensive disease control after one year, including symptomatic, endoscopic and histologic remission, normalized biomarkers and no corticosteroid use. In the VIVID-1 Crohn’s disease trial, 20.4% achieved corticosteroid-free deep remission. The results also included patients who had previously failed biologic therapies, potentially supporting Omvoh’s commercial positioning. Omvoh clinical data
• Positive Sentiment: Pipeline expansion adds longer-term growth potential. Lilly announced oncology collaborations with Adlai Nortye and Prelude Therapeutics, including evaluation of Adlai’s investigational AN4035 with cetuximab. The partnerships broaden Lilly’s cancer research pipeline and exposure to the growing oncology market. Adlai Nortye collaboration
• Neutral Sentiment: Additional pipeline updates provide background support. Lilly is advancing studies of donanemab in India and lebrikizumab in eczema, while investors remain focused on the potential of retatrutide and other next-generation weight-loss treatments.
• Neutral Sentiment: Upcoming earnings could add volatility. Lilly will report third-quarter 2026 results on October 29. Expectations center on continued strong revenue and earnings growth, particularly from its diabetes and obesity medicines. Lilly earnings announcement
• Negative Sentiment: Valuation remains a risk. After a substantial multiyear rally and trading near its 52-week high, Lilly’s premium valuation leaves the stock dependent on continued exceptional growth and successful pipeline execution. Speculation about a stock split is not a fundamental catalyst.

Eli Lilly and Company Price Performance

Shares of LLY stock opened at $1,253.94 on Friday. The stock's 50-day simple moving average is $1,178.66 and its 200-day simple moving average is $1,106.93. The firm has a market capitalization of $1.18 trillion, a price-to-earnings ratio of 42.08, a PEG ratio of 1.58 and a beta of 0.46. The company has a debt-to-equity ratio of 1.41, a quick ratio of 1.00 and a current ratio of 1.35. Eli Lilly and Company has a fifty-two week low of $783.85 and a fifty-two week high of $1,292.65.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share for the quarter, beating the consensus estimate of $6.40 by $1.98. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%. The business had revenue of $22.97 billion for the quarter, compared to the consensus estimate of $20.82 billion. During the same quarter in the previous year, the business earned $6.31 EPS. The company's quarterly revenue was up 47.7% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. As a group, equities analysts forecast that Eli Lilly and Company will post 34.28 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have weighed in on the stock. Leerink Partners upped their price target on shares of Eli Lilly and Company from $1,119.00 to $1,232.00 and gave the stock an "outperform" rating in a research report on Thursday, June 25th. BMO Capital Markets restated an "outperform" rating on shares of Eli Lilly and Company in a research report on Thursday, October 1st. Weiss Ratings upgraded shares of Eli Lilly and Company from a "buy (b-)" rating to a "buy (b)" rating in a research report on Wednesday, August 26th. Morgan Stanley increased their price target on Eli Lilly and Company from $1,419.00 to $1,430.00 and gave the company an "overweight" rating in a report on Wednesday, October 7th. Finally, HSBC raised their price target on Eli Lilly and Company from $850.00 to $940.00 and gave the stock a "reduce" rating in a research note on Thursday, September 10th. One analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, three have given a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, Eli Lilly and Company currently has an average rating of "Moderate Buy" and a consensus price target of $1,313.43.

Insiders Place Their Bets

In other Eli Lilly and Company news, CAO Donald Zakrowski sold 2,000 shares of the company's stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $1,185.01, for a total value of $2,370,020.00. Following the sale, the chief accounting officer owned 1,526 shares in the company, valued at approximately $1,808,325.26. This represents a 56.72% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of the stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the transaction, the executive vice president owned 54,147 shares in the company, valued at $63,628,139.70. This represents a 10.72% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 13,500 shares of company stock worth $15,958,170. Corporate insiders own 0.14% of the company's stock.

About Eli Lilly and Company

Eli Lilly and Company is a global pharmaceutical company headquartered in Indianapolis, Indiana. Founded in 1876 by Colonel Eli Lilly, the company researches, develops, manufactures and markets medicines for a range of conditions, including diabetes, obesity, cancer, immunological disorders, neurological diseases and pain.

Its products include Mounjaro and Zepbound, which contain tirzepatide and are used for type 2 diabetes and chronic weight management, respectively. Other key medicines include Trulicity for diabetes, Verzenio for certain breast cancers, Taltz for inflammatory and autoimmune conditions, Humalog insulin, and Kisunla for early symptomatic Alzheimer's disease.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.